Phase I/II trial of DPX 0907 cancer vaccine in patients with breast and ovarian cancers

Trial Profile

Phase I/II trial of DPX 0907 cancer vaccine in patients with breast and ovarian cancers

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 03 May 2018

At a glance

  • Drugs DPX 0907 (Primary)
  • Indications Breast cancer; Ovarian cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 03 May 2018 According to an IMV media release, Immunovaccine has changed its name to IMV.
    • 20 Apr 2015 Status changed from planning to withdrawn prior to enrolment, according to an Immunovaccine media release.
    • 20 Apr 2015 According to an Immunovaccine media release, this trial will no longer proceed due to unforeseen extended delays at the clinical site.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top